

Associate Editors

xi

Contributors

xiii

Current Management of Small Bowel Obstruction

Martin Donald Zielinski and Michael Patrick Bannon

Pathogenesis	1
Pathophysiology	6
Diagnosis and workup	7
History and physical examination	8
Laboratory testing	8
Imaging	9
Management	9
Resuscitation	9
Deciding between operative or nonoperative management	10
Nonoperative management	13
Operative management	15
Management of obstruction by specific etiology	17
Adhesive disease	17
Malignant SBO	18
Early postoperative SBO	19
Hernia	21
Crohn disease	21
Radiation enteritis	22
Summary	23
References	23

Screening for Colorectal Cancer

Jin He and Jonathan E. Efron

Endoscopy	31
Alternative to colonoscopy	33
Blood markers	33
Stool markers	35
Virtual colonoscopy or compute tomographic colonography	37
Video capsule endoscopy: pillcam colon	38
Summary	39
References	40

Varicose Vein: Current Management

Beejay A. Feliciano and Michael C. Dalsing

Etiology	45
Signs, symptoms, evaluation, and treatment	45
Radiofrequency ablation	46
Endovenous laser surgery	52
RFA versus EVLS	55
Sclerotherapy	57
Transilluminated powered phlebectomy system	59
Summary	59
References	60

Geographic Variation in Health Care and the Affluence-Poverty Nexus

Richard A. Cooper

Evolution of 30%	63
Birth of the atlas	64
Methodological pitfalls	65
Unexplained variation	65
Adjusting for race and poverty	65
Medicare as the source of data	66
Medicare doing better versus medicare catching up	66
Employing death as the outcome	68
Alternative estimates = “more is more”	69
Quintiles model	70
Random exposure to medicare	71
Failure to discern differences	71
Crafting the dartmouth message	72
Propelling 30% into president Obama’s office	72
The compelling imperative	74
The affluence-poverty nexus	75
The communal level	76
The individual level	77
The intersection of poverty and urbanization	78
The “poverty effect”: how much?	78
Summary	78
References	79

Endovascular Approaches to Arteriovenous Fistula

Jennifer A. Sexton and John J. Ricotta

Etiology	83
Acquired AVF	83
Congenital AVF or AVMs	84
Pathophysiology of AVFs	84
Signs and symptoms of AVFs	87
Diagnosis of AVFs	88
Physical examination	88

Imaging	89
Management of AVFs: The role of endovascular therapy	92
Acquired AVF	93
AVMs	95
Summary	99
References	99

Local and Regional Control in Breast Cancer: Role of Sentinel Node Biopsy

Armando E. Giuliano and Soo Hwa Han

Patient selection	101
Technical aspects of SLND	102
Impact of patient and tumor characteristics on SLND success	105
The role of SLND in axillary staging	105
Histopathologic analysis of the sentinel node	107
SLND and axillary recurrence in patients with sentinel node-negative cancer	108
SLND and axillary recurrence in patients with sentinel node-positive cancer	110
Summary	112
References	113

Stem Cells in Acute Liver Failure

Russell N. Wesson and Andrew M. Cameron

Challenges presented by acute liver failure	117
Normal mechanisms of hepatic regeneration	118
Involvement of hematopoietic stem cells in liver regeneration	119
Stem cells aid in liver recovery	120
Stem cell mobilization in hematologic disease	121
Therapeutic mobilization of stem cells using different agents	123
Importance of the SDF1/CXCR4 axis in trafficking of HSCs	123
Beneficial effects of stem cell mobilization in acute liver failure	124
Summary	127
References	127

Is There a Role for Bowel Preparation and Oral or Parenteral Antibiotics In Infection Control in Contemporary Colon Surgery?

Susan Galandiuk, Donald E. Fry, Hiram C. Polk Jr

Parenteral antibiotic administration	133
Mechanical bowel preparation	133
Oral antibiotic use	135
Summary	137
Acknowledgments	138
References	138

Oral Antibiotics to Prevent Surgical Site Infections Following Colon Surgery

Danielle Fritze, Michael J. Englesbe, and Darrell A. Campbell Jr

Theory	141
History	142
Current state of the literature	146
Current state of practice	147
The Michigan experience	147
Future directions	149
References	150

Pancreatic Necrosectomy

Jordan R. Stern and Jeffrey B. Matthews

Definition	156
Pathophysiology and prevention of sterile and infected necrosis	156
Diagnosis	160
Surgical indications and timing of intervention	162
Surgical techniques	163
Open pancreatic necrosectomy	163
Videoscopic surgical techniques	165
Endoluminal therapy	168
Image-guided drainage procedures	169
Hybrid procedures	169
Long-term outcomes	170
Summary and recommendations	170
References	172

The Impact of Health Care Reform on Surgery

Donald D. Trunkey

Safety net hospitals	178
References	184

Glucose Elevations and Outcome in Critically Injured Trauma Patients

Joseph J. DuBose and Thomas M. Scalea

Pathophysiology of stress hyperglycemia	187
Insulin therapy and strict glucose control in critical illness	188
Hyperglycemia risk and treatment among trauma populations	190
Controversies and future directions	191
Timing of glucose control initiation	192
What is the ideal goal range?	192
Increased ICU workload associated with tight glycemic control	193
The risks of tight glycemic control	193
Future directions	194
Summary	194
References	195

Advances in the Surgical Management of Gastrointestinal Stromal Tumor

Umer I. Chaudhry and Ronald P. DeMatteo

Clinical presentation	198
Diagnosis and evaluation	198
Prognostic factors	199
Treatment	200
Primary GIST	201
Adjuvant imatinib	202
Neoadjuvant imatinib	203
Recurrent GIST	203
Summary	206
References	206

Choledochoceles: Are They Choledochal Cysts?

Kathryn M. Ziegler and Nicholas J. Zyromski

Choledochal cysts and choledochoceles: accepted classification	211
Choledochoceles	213
Pathophysiology	214
Demographics and presenting symptoms	215
Diagnostic evaluation	216
Ductal anatomic abnormalities	217
Associated neoplasia	218
Endoscopic, percutaneous, and surgical management	218
Outcomes	220
Summary	220
References	221

What Does Ulceration of a Melanoma Mean for Prognosis?

Glenda G. Callender and Kelly M. McMasters

Ulceration as negative prognostic factor	225
Ulceration as predictor of sentinel lymph node involvement	226
Ulceration as predictor of response to adjuvant IFN therapy	228
Ulceration and underlying molecular mechanisms	232
Summary	234
References	234

Influence of Surgical Volume on Operative Failures for Hyperparathyroidism

Barbara Zarebczan and Herbert Chen

Hyperparathyroidism	237
Surgical failure	239
Reoperation for hyperparathyroidism	241
Preoperative assessment	242
Operative technique	245

Summary	246
References	247

Perioperative Normothermia During Major Surgery: Is It Important?

Nestor F. Esnaola and David J. Cole

Pathophysiology of PH	249
Adverse effect of hypothermia in the surgical patient	250
Shivering	250
Cardiac morbidity	251
Coagulopathy	251
SSIs	251
Temperature monitoring	255
Prevention of PH	256
Airway heating/humidification	256
Cutaneous warming	257
Warmed intravenous fluids	258
Relative benefit of perioperative interventions to maintain normothermia	258
Summary	260
References	260

Surgical Management of Hereditary Nonpolyposis Colorectal Cancer

Matthew F. Kalady

Clarification of terms: HNPCC and Lynch syndrome	265
Cancer risk in Lynch syndrome	267
Surveillance for colorectal cancer	267
Surgical indications and surgical management	267
Colon and colon cancer	267
Rectal cancer	269
Management of the uterus and ovaries in Lynch syndrome	271
Familial colorectal cancer type X	271
Summary	272
References	272

How to Change General Surgery Residency Training

Steven C. Stain

References	284
------------	-----

Recent Advances in the Diagnosis and Treatment of Gastrointestinal Carcinoids

Joseph Valentino and B. Mark Evers

Etiology	285
Carcinoid syndrome	286
Diagnosis and staging	286

History and physical presentation	286
Laboratory studies	287
Imaging	287
Surgical treatment	289
Surgical treatment of localized disease	289
Surgical treatment of metastatic disease	292
Medical treatment	293
Somatostatin analog therapy	293
Cytotoxic chemotherapy	295
Molecular targeted therapy	295
Surveillance	296
Prognosis	296
Acknowledgments	296
References	296

**The Past, Present, and Future of Biomarkers:
A Need for Molecular Beacons for the Clinical
Management of Pancreatic Cancer**

Jonathan R. Brody, Agnieszka K. Witkiewicz, and
Charles J. Yeo

Current biomarkers used for the clinical management of PDA	303
The limitations and usefulness of the available conventional markers	304
CA19-9	304
CEA	306
CA-125 and final thoughts on conventional markers	306
Novel markers (including early detection) of pancreatic cancer	307
Emerging and alternative molecular (predictive) biomarkers for the treatment of PDA	309
HuR as a biomarker in pancreatic cancer	309
Previously reported clinical correlates and predictors of standard of care therapy for PDA (gemcitabine)	312
HuR is an unprecedented predictive marker for gemcitabine response in patients with PDA	313
Another current example: the development of growth factor receptors in PDA as relevant biomarkers	314
Future exploratory work: the need for the integration of emerging technologies and systems biology to help create roadmaps for diagnosis and prediction of therapy	314
Final thoughts	316
References	317

Robotic-Assisted Major Pancreatic Resection

H.J. Zeh III, David L. Bartlett, and A. James Moser

Historical landmarks in development of the pancreaticoduodenectomy	323
Potential advantages of minimally invasive major pancreatic resection	324
Limitations of laparoscopic techniques for pancreaticoduodenectomy	324
Robotic-assisted minimally invasive pancreaticoduodenectomy	325
Selection criteria for robotic-assisted pancreaticoduodenectomy	325

Technique of robotic-assisted pancreaticoduodenectomy	326
Instruments	327
Patient position	327
Port position	327
Step 1	327
Step 2: Division of the gastrocolic omentum and proximal duodenum	328
Step 3: Docking the robot	329
Step 4: Dissection of the porta hepatis and division of the bile duct	329
Step 5: Dissection of the pancreatic neck and mobilization of the portal vein	330
Step 6: Dissection of the retroperitoneal margin	331
Step 7	332
Pittsburgh experience with robotic-assisted major pancreatic resection	334
Comparison of outcomes following robotic-assisted major pancreatic resections with selected laparoscopic and open series	337
Limitations of major pancreatectomy associated with the current robotic platform	338
Emerging innovations in robotic technology	339
Summary	339
References	339

Immunotherapy for Metastatic Solid Cancers

Simon Turcotte and Steven A. Rosenberg

Background of cancer immunology	341
Nonspecific immunotherapy	344
Stimulation of effector T cells	344
Blockade of negative regulators of T-cell function	345
Summary and new directions	347
Active immunization approaches (cancer vaccines)	347
Summary and new directions	349
Adoptive cell transfer of activated immune cells with antitumor activity	350
Adoptive cell transfer using tumor-infiltrating lymphocytes	350
Adoptive cell transfer using genetically modified autologous peripheral blood lymphocytes	351
Summary and future directions	355
Summary	356
References	356

Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the Surgical Patient

Taki Galanis, Walter K. Kraft, and Geno J. Merli

Cause of VTE in the surgical patient	361
VTE risk factor assessment before surgery	362
Modalities of prophylaxis	363
Unfractionated heparin	363
Low-molecular-weight heparin and pentasaccharide	364
Warfarin	367
Mechanical prophylaxis modalities	367

Aspirin	368
VTE prophylaxis for surgery	368
Orthopedic surgery	368
Urological surgery	370
Neurosurgery	372
Gynecologic surgery	373
General surgery	373
Extended prophylaxis for DVT and PE	376
New oral anticoagulants	378
Apixaban	378
Rivaroxaban	380
Dabigatran	383
References	386
Index	391